Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Metasulfurous Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metasulfurous Acid SCHEMBL28281399 | 0.75 | ALDH1A1 (0.35) | TP53 | |
| 1,3-Butanediol SCHEMBL5769439 | 0.75 | TP53 (0.43) | TP53 | |
| 1,3-Butanediol SCHEMBL956903 | 0.75 | TDP1 (0.40) | — | |
| Choline SCHEMBL28213029 | 0.73 | MEN1 (0.48) | — | |
| 1,3-Butanediol SCHEMBL575403 | 0.73 | TDP1 (0.38) | TP53 | |
| Metasulfurous Acid SCHEMBL1853583 | 0.72 | TP53 (0.50) | TP53 | |
| Metasulfurous Acid SCHEMBL29171657 | 0.72 | MEN1 (0.41) | — | |
| 1,3-Butanediol SCHEMBL222874 | 0.72 | — | — | |
| 1,3-Butanediol SCHEMBL227565 | 0.72 | — | — | |
| 1,3-Butanediol SCHEMBL3427715 | 0.72 | TDP1 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036321-B2 | Compositions and methods for treating or preventing multiple organ dysfunction syndrome | VIVACELLE BIO, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240091176-A1 | EPINEPHRINE FORMULATIONS | COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION | 2024-03-21 | — | — | US | disclosed |
| US-20240058281-A1 | EPINEPHRINE FORMULATIONS | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2024-02-22 | — | — | US | disclosed |
| US-20240009126-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING MULTIPLE ORGAN DYSFUNCTION SYNDROME | VIVACELLE BIO INC. | 2024-01-11 | — | — | US | disclosed |
| US-20230100523-A1 | EPINEPHRINE FORMULATIONS | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2023-03-30 | — | — | US | disclosed |
| EP-4126250-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING MULTIPLE ORGAN DYSFUNCTION SYNDROME | Vivacelle Bio, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| EP-4021424-A1 | HEMOGLOBIN-BASED NANOPARTICLES FOR OXYGEN DELIVERY | Ohio State Innovation Foundation (US) | 2022-07-06 | — | — | EP | disclosed |
| US-11337938-B2 | Epinephrine formulations | PAR PHARMACEUTICAL, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| WO-2021203143-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING MULTIPLE ORGAN DYSFUNCTION SYNDROME | VIVACELLE BIO, INC. (US) | 2021-10-07 | — | — | WO | disclosed |
| EP-2663326-B2 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS RELATED TO LACK OF BLOOD SUPPLY, SHOCK AND NEURONAL INJURIES | VIVACELLE BIO INC (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-2663326-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS RELATED TO LACK OF BLOOD SUPPLY, SHOCK AND NEURONAL INJURIES | Simpkins, Cuthbert O. (US) | 2013-11-20 | — | — | EP | disclosed |
| WO-2012096697-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS RELATED TO LACK OF BLOOD SUPPLY, SHOCK AND NEURONAL INJURIES | SIMPKINS CUTHBERT O (US) | 2012-07-19 | — | — | WO | disclosed |
| US-20120125847-A1 | METHODS FOR REMOVING PATHOGENS FROM A PLATELET PREPARATION | BIOVEC TRANSFUSION, LLC (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120087956-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS RELATED TO LACK OF BLOOD SUPPLY, SHOCK AND NEURONAL INJURIES | VIVACELLE BIO, INC. | 2012-04-12 | — | — | US | disclosed |
| US-20100196461-A1 | RESUSCITATION FLUID | VIVACELLE BIO, INC. | 2010-08-05 | — | — | US | disclosed |
| WO-2010087986-A2 | RESUSCITATION FLUID | SIMPKINS CUTHBERT O (US) | 2010-08-05 | — | — | WO | disclosed |
| US-7417118-B2 | Pharmaceutical composition containing artificial oxygen carrier | NIPRO CORPORATION (JP) | 2008-08-26 | — | — | US | disclosed |
| EP-1466649-B1 | Pharmaceutical composition containing artificial oxygen carrier | NIPRO CORP (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-20040258745-A1 | Pharmaceutical composition containing artificial oxygen carrier | NIPRO CORPORATION (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1466649-A1 | Pharmaceutical composition containing artificial oxygen carrier | Nipro Corporation (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11337938-B2 | Epinephrine formulations | ADRA1A, ADRB1, ADRA2C | TP53 4728/4885 |
| US-20240091176-A1 | EPINEPHRINE FORMULATIONS | ADRA1A, ADRB1, ADRA2C | TP53 4728/4885 |
| US-20230100523-A1 | EPINEPHRINE FORMULATIONS | ADRA1A, ADRB1, ADRA2C | TP53 4728/4885 |
| US-20240058281-A1 | EPINEPHRINE FORMULATIONS | ADRA1A, ADRB1, ADRA2C | TP53 4728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.